Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial
Abstract Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder significantly decreasing patients’ lives of quality and placing huge economic burden on our society. Existing studies indicated that the therapeutic effects maintained for a period of time after the treatments were...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/15c097a34cb24b229a7aa5256b436878 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:15c097a34cb24b229a7aa5256b436878 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:15c097a34cb24b229a7aa5256b4368782021-12-02T15:23:08ZAssessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial10.1038/s41598-021-92990-72045-2322https://doaj.org/article/15c097a34cb24b229a7aa5256b4368782021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92990-7https://doaj.org/toc/2045-2322Abstract Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder significantly decreasing patients’ lives of quality and placing huge economic burden on our society. Existing studies indicated that the therapeutic effects maintained for a period of time after the treatments were discontinued. It is clinically important to assess these post-treatment therapeutic effects (PTTE), which prevent IBS from relapsing. To assess the PTTE in pinaverium treatment and obtain high-quality evidence to justify the use of PTTE for long-term IBS management, we performed this controlled, double blind study on patients with IBS who were randomized to pinaverium 50 mg (n = 132) or placebo (n = 132), three times daily, for 4 weeks, and were followed up for 57 weeks after the treatments. The primary endpoints were abdominal pain and stool consistency. The secondary endpoints were pain frequency and stool frequency. The tertiary endpoints were global overall symptom and adverse events. Three days after pinaverium was discontinued, endpoints rebounded only 23.2–42.8% (P < 0.015 cf. placebo). The PTTE (P < 0.05 cf. placebo) lasted 9–17 weeks, which is similar to other antispasmodics with a 15-week treatment in striking contrast to ≥ 1 year PTTE in cognitive behavior therapy and < 1 week PTTE in serotonin antagonist treatment indicating that PTTE length markedly depends on the medication class used for the treatment and less depends on treatment length. After 17 weeks, the stage could be considered as an IBS natural history [no significant differences between pinaverium and placebo (all endpoints’ P’s > 0.05)], during which an average of 51.5–56.4% of patients (pool pinaverium and placebo data together) had IBS symptoms. These results provide clinical insights into efficient and cost-effective management of refractory IBS, and lend support to the IBS management that the selection of a therapy should consider both its effectiveness during treatment and its PTTE after the treatment. Trial registration number: NCT02330029 (16/08/2016).Liang ZhengWeimin LuQi XiaoYaoliang LaiHeng FanYuling SunDawei HuangYuanyuan WangZhen LiZhengyan JiangXingxing LiuLijuan ZhangDongmei ZuoZhexing ShouQing TangHuisuo HuangYongqiang YangZongxiang TangJun XiaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Liang Zheng Weimin Lu Qi Xiao Yaoliang Lai Heng Fan Yuling Sun Dawei Huang Yuanyuan Wang Zhen Li Zhengyan Jiang Xingxing Liu Lijuan Zhang Dongmei Zuo Zhexing Shou Qing Tang Huisuo Huang Yongqiang Yang Zongxiang Tang Jun Xiao Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial |
| description |
Abstract Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder significantly decreasing patients’ lives of quality and placing huge economic burden on our society. Existing studies indicated that the therapeutic effects maintained for a period of time after the treatments were discontinued. It is clinically important to assess these post-treatment therapeutic effects (PTTE), which prevent IBS from relapsing. To assess the PTTE in pinaverium treatment and obtain high-quality evidence to justify the use of PTTE for long-term IBS management, we performed this controlled, double blind study on patients with IBS who were randomized to pinaverium 50 mg (n = 132) or placebo (n = 132), three times daily, for 4 weeks, and were followed up for 57 weeks after the treatments. The primary endpoints were abdominal pain and stool consistency. The secondary endpoints were pain frequency and stool frequency. The tertiary endpoints were global overall symptom and adverse events. Three days after pinaverium was discontinued, endpoints rebounded only 23.2–42.8% (P < 0.015 cf. placebo). The PTTE (P < 0.05 cf. placebo) lasted 9–17 weeks, which is similar to other antispasmodics with a 15-week treatment in striking contrast to ≥ 1 year PTTE in cognitive behavior therapy and < 1 week PTTE in serotonin antagonist treatment indicating that PTTE length markedly depends on the medication class used for the treatment and less depends on treatment length. After 17 weeks, the stage could be considered as an IBS natural history [no significant differences between pinaverium and placebo (all endpoints’ P’s > 0.05)], during which an average of 51.5–56.4% of patients (pool pinaverium and placebo data together) had IBS symptoms. These results provide clinical insights into efficient and cost-effective management of refractory IBS, and lend support to the IBS management that the selection of a therapy should consider both its effectiveness during treatment and its PTTE after the treatment. Trial registration number: NCT02330029 (16/08/2016). |
| format |
article |
| author |
Liang Zheng Weimin Lu Qi Xiao Yaoliang Lai Heng Fan Yuling Sun Dawei Huang Yuanyuan Wang Zhen Li Zhengyan Jiang Xingxing Liu Lijuan Zhang Dongmei Zuo Zhexing Shou Qing Tang Huisuo Huang Yongqiang Yang Zongxiang Tang Jun Xiao |
| author_facet |
Liang Zheng Weimin Lu Qi Xiao Yaoliang Lai Heng Fan Yuling Sun Dawei Huang Yuanyuan Wang Zhen Li Zhengyan Jiang Xingxing Liu Lijuan Zhang Dongmei Zuo Zhexing Shou Qing Tang Huisuo Huang Yongqiang Yang Zongxiang Tang Jun Xiao |
| author_sort |
Liang Zheng |
| title |
Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial |
| title_short |
Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial |
| title_full |
Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial |
| title_fullStr |
Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial |
| title_full_unstemmed |
Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial |
| title_sort |
assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/15c097a34cb24b229a7aa5256b436878 |
| work_keys_str_mv |
AT liangzheng assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT weiminlu assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT qixiao assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT yaolianglai assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT hengfan assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT yulingsun assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT daweihuang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT yuanyuanwang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT zhenli assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT zhengyanjiang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT xingxingliu assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT lijuanzhang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT dongmeizuo assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT zhexingshou assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT qingtang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT huisuohuang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT yongqiangyang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT zongxiangtang assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial AT junxiao assessingtheposttreatmenttherapeuticeffectofpinaveriuminirritablebowelsyndromearandomizedcontrolledtrial |
| _version_ |
1718387310403256320 |